DK1297013T3 - Anvendelse af TACI som antitumormiddel - Google Patents

Anvendelse af TACI som antitumormiddel

Info

Publication number
DK1297013T3
DK1297013T3 DK01927474T DK01927474T DK1297013T3 DK 1297013 T3 DK1297013 T3 DK 1297013T3 DK 01927474 T DK01927474 T DK 01927474T DK 01927474 T DK01927474 T DK 01927474T DK 1297013 T3 DK1297013 T3 DK 1297013T3
Authority
DK
Denmark
Prior art keywords
taci
mammal
antitumor agent
reagent
administering
Prior art date
Application number
DK01927474T
Other languages
Danish (da)
English (en)
Inventor
Christine Ambrose
Jeffrey Thompson
Pascal Schneider
Paul Rennert
Original Assignee
Biogen Idec Inc
Apoxis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Apoxis Sa filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1297013T3 publication Critical patent/DK1297013T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK01927474T 2000-04-27 2001-04-27 Anvendelse af TACI som antitumormiddel DK1297013T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19994600P 2000-04-27 2000-04-27

Publications (1)

Publication Number Publication Date
DK1297013T3 true DK1297013T3 (da) 2006-12-27

Family

ID=22739664

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01927474T DK1297013T3 (da) 2000-04-27 2001-04-27 Anvendelse af TACI som antitumormiddel

Country Status (13)

Country Link
EP (1) EP1297013B1 (de)
JP (1) JP2004513876A (de)
AT (1) ATE336509T1 (de)
AU (2) AU2001253920B2 (de)
CA (1) CA2404945C (de)
CY (1) CY1105788T1 (de)
DE (1) DE60122337T2 (de)
DK (1) DK1297013T3 (de)
ES (1) ES2271004T3 (de)
NZ (1) NZ521629A (de)
PT (1) PT1297013E (de)
SI (1) SI1297013T1 (de)
WO (1) WO2001081417A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
AU2001285066B2 (en) 2000-08-18 2006-06-29 Human Genome Sciences, Inc. Binding polypeptides for B lymphocyte stimulator protein (BLYS)
WO2002046231A2 (en) * 2000-12-07 2002-06-13 The University Of British Columbia Caml-binding peptides
EA010594B1 (ru) * 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
CA2446734A1 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
PT2272868E (pt) 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
EP1709072A1 (de) 2004-01-29 2006-10-11 Genentech, Inc. Varianten der extrazellulären domäne von bcma und verwendungen dafür
CN101262876A (zh) * 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
WO2007019573A2 (en) * 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
CN111655280B (zh) * 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
WO2021226551A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
TR200101998T2 (tr) * 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon

Also Published As

Publication number Publication date
ATE336509T1 (de) 2006-09-15
WO2001081417A3 (en) 2002-06-20
ES2271004T3 (es) 2007-04-16
SI1297013T1 (sl) 2007-06-30
AU5392001A (en) 2001-11-07
PT1297013E (pt) 2006-12-29
EP1297013A2 (de) 2003-04-02
EP1297013B1 (de) 2006-08-16
CA2404945C (en) 2010-02-09
DE60122337T2 (de) 2007-08-16
JP2004513876A (ja) 2004-05-13
NZ521629A (en) 2004-05-28
CY1105788T1 (el) 2011-02-02
DE60122337D1 (de) 2006-09-28
WO2001081417A2 (en) 2001-11-01
CA2404945A1 (en) 2001-11-01
AU2001253920B2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE336509T1 (de) Verwendung von taci als antitumormittel
TR200000782T2 (tr) Resorsinol türevleri.
NO20060600L (no) Spesifikke bindingsmidler for hepatocytt vekstfaktorer
CR6393A (es) Moduladores de ccr5
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
BR0110751A (pt) Dispositivo
BR0111981A (pt) herbicidas de piridina substituìda
NO20014756L (no) C(10)-heterosubstituerte acetattaxaner som antitmormidler
DE60125417D1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
TR200102742T2 (tr) Rezorsinol türevleri
EA200800889A1 (ru) Гексагидроциклооктилпиразольные каннабиноидные модуляторы
SE0400208D0 (sv) Chemical compounds
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
BRPI0512310A (pt) compostos quìmicos
WO2006042055A3 (en) Ionized performance fabric
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
TW200603785A (en) Compositions containing reduced coenzyme Q10 and carotenoid
NO20014758L (no) C(7)-heterosubstituerte acetattaxaner som antitumormidler
ES2174297T3 (es) Nuevos derivados de piranosidos.
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
TWI349545B (en) Pharmaceutical composition
BR0316245A (pt) Atividade antimicrobiana de espécie de oxigênio reativo produtora de anticorpos
NO20064837L (no) Monoazofaregestoffer